|
Name |
4-Deoxybostrycin
|
Molecular Formula | C16H16O7 | |
IUPAC Name* |
(2R,3S)-2,3,5,8-tetrahydroxy-6-methoxy-3-methyl-2,4-dihydro-1H-anthracene-9,10-dione
|
|
SMILES |
C[C@@]1(CC2=C(C[C@H]1O)C(=O)C3=C(C2=O)C(=C(C=C3O)OC)O)O
|
|
InChI |
InChI=1S/C16H16O7/c1-16(22)5-7-6(3-10(16)18)13(19)11-8(17)4-9(23-2)15(21)12(11)14(7)20/h4,10,17-18,21-22H,3,5H2,1-2H3/t10-,16+/m1/s1
|
|
InChIKey |
IPVKWDJQQALEDL-HWPZZCPQSA-N
|
|
Synonyms |
4-Deoxybostrycin; F09N14I154; CHEMBL2047316; UNII-F09N14I154; 9,10-ANTHRACENEDIONE, 1,2,3,4-TETRAHYDRO-2,3,5,8-TETRAHYDROXY-7-METHOXY-2-METHYL-, (2S,3R)-; 9,10-Anthracenedione, 1,2,3,4-tetrahydro-2,3,5,8-tetrahydroxy-7-methoxy-2-methyl-, (2S-cis)-
|
|
CAS | 21879-83-4 | |
PubChem CID | 135565267 | |
ChEMBL ID | CHEMBL2047316 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 320.29 | ALogp: | 1.1 |
HBD: | 4 | HBA: | 7 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 124.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 23 | QED Weighted: | 0.571 |
Caco-2 Permeability: | -5.43 | MDCK Permeability: | 0.00000545 |
Pgp-inhibitor: | 0.037 | Pgp-substrate: | 0.996 |
Human Intestinal Absorption (HIA): | 0.077 | 20% Bioavailability (F20%): | 0.475 |
30% Bioavailability (F30%): | 0.072 |
Blood-Brain-Barrier Penetration (BBB): | 0.011 | Plasma Protein Binding (PPB): | 94.03% |
Volume Distribution (VD): | 0.73 | Fu: | 12.02% |
CYP1A2-inhibitor: | 0.312 | CYP1A2-substrate: | 0.923 |
CYP2C19-inhibitor: | 0.016 | CYP2C19-substrate: | 0.071 |
CYP2C9-inhibitor: | 0.12 | CYP2C9-substrate: | 0.551 |
CYP2D6-inhibitor: | 0.025 | CYP2D6-substrate: | 0.182 |
CYP3A4-inhibitor: | 0.101 | CYP3A4-substrate: | 0.194 |
Clearance (CL): | 16.443 | Half-life (T1/2): | 0.911 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.231 |
Drug-inuced Liver Injury (DILI): | 0.697 | AMES Toxicity: | 0.504 |
Rat Oral Acute Toxicity: | 0.024 | Maximum Recommended Daily Dose: | 0.026 |
Skin Sensitization: | 0.9 | Carcinogencity: | 0.03 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.572 |
Respiratory Toxicity: | 0.209 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003536 | 0.694 | D01XWG | 0.323 | ||||
ENC000941 | 0.667 | D07VLY | 0.315 | ||||
ENC004459 | 0.640 | D0C9XJ | 0.315 | ||||
ENC005550 | 0.605 | D07MGA | 0.312 | ||||
ENC006066 | 0.513 | D01XDL | 0.293 | ||||
ENC006089 | 0.506 | D0T5XN | 0.270 | ||||
ENC006067 | 0.500 | D0T8EH | 0.265 | ||||
ENC000958 | 0.488 | D0C1SF | 0.260 | ||||
ENC005551 | 0.487 | D0J4IX | 0.255 | ||||
ENC005208 | 0.481 | D08LTU | 0.254 |